Psychiatry
Specific Phobia
4
Pipeline Programs↗
0
Active Trials↗
2
Companies Involved↗
Specific Phobia is an early-stage landscape with 4 programs across 2 companies. The most active players are AstraZeneca, AbbVie. 1 therapy is approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 31
Approved1
Analysis
Trial Status
3
clinical trials
Completed3 · 100%
Clinical Trials
Trial Activity
Study of Escitalopram in the Treatment of Specific Phobia
Completed·—·Phase 2/3·NCT00121069·12 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)